{{Underlinked|date=February 2017}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 444167725
| IUPAC_name = (2''E'')-3,7-dimethylocta-2,6-dien-1-yl (4''E'',8''E'')-5,9,13-trimethyltetradeca-4,8,12-trienoate
| image = Gefarnate.svg
| alt = Skeletal formula
| width = 320
| image2 = Gefarnate-3D-spacefill.png
| alt2 = Space-filling model

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|gefarnate}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 51-77-4
| ATC_prefix = A02
| ATC_suffix = BX07
| PubChem = 5282182
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 2105085
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 1ISE2Y6ULA
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01529
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 4445377

<!--Chemical data-->
| C=27 | H=44 | O=2 
| molecular_weight = 400.637 g/mol
| smiles = CC(C)=CCC/C(C)=C/CC/C(C)=C/CCC(=O)OC/C=C(C)/CCC=C(C)C
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C27H44O2/c1-22(2)12-8-14-24(5)16-10-17-25(6)18-11-19-27(28)29-21-20-26(7)15-9-13-23(3)4/h12-13,16,18,20H,8-11,14-15,17,19,21H2,1-7H3/b24-16+,25-18+,26-20+
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = ZPACYDRSPFRDHO-ROBAGEODSA-N
}}
'''Gefarnate''' is a drug used for the treatment of [[gastric ulcer]]s.<ref name="pmid16079487">{{cite journal |vauthors=Ohta Y, Kobayashi T, Imai Y, Inui K, Yoshino J, Nakazawa S |title=Effect of gefarnate on acute gastric mucosal lesion progression in rats treated with compound 48/80, a mast cell degranulator, in comparison with that of teprenone |journal=Biol. Pharm. Bull. |volume=28 |issue=8 |pages=1424–30 |date=August 2005 |pmid=16079487 |doi= 10.1248/bpb.28.1424|url=https://www.jstage.jst.go.jp/article/bpb/28/8/28_8_1424/_article}}</ref>

It also has been proposed for use in the treatment of [[dry eye syndrome]].<ref name="pmid18560615">{{cite journal |vauthors=Peral A, Domínguez-Godínez CO, Carracedo G, Pintor J |title=Therapeutic targets in dry eye syndrome |journal=Drug News Perspect. |volume=21 |issue=3 |pages=166–76 |date=April 2008 |pmid=18560615 |doi= |url=}}</ref><ref name="pmid17216084">{{cite journal|vauthors=Gipson IK, Hori Y, Argüeso P |title=Character of ocular surface mucins and their alteration in dry eye disease |journal=Ocul Surf |volume=2 |issue=2 |pages=131–48 |date=April 2004 |pmid=17216084 |doi=10.1016/s1542-0124(12)70149-0 |url=http://www.theocularsurface.com/ArticlesV2N2-Gipson.htm }}{{dead link|date=January 2017 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>

==References==
{{reflist}}

{{Drugs for peptic ulcer and GORD}}

[[Category:Drugs acting on the gastrointestinal system and metabolism]]
[[Category:Carboxylate esters]]
[[Category:Polyolefins]]


{{alkene-stub}}
{{gastrointestinal-drug-stub}}